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Background
Regular transfusion in thalassemia major patients increases
life expectancy and improves quality of life, but results in
iron overload, which had toxic effects to organs including
endocrine glands. The introduction of iron chelation ther-
apy has reduced its toxicity, but complications may still
occur. In Indonesia, most of our patients did not receive
optimal iron chelation therapy, which might result in
higher prevalence of endocrine complications.
Aims
To find out the endocrinopathies profile in thalassemia
major patients in Thalassemia Center Jakarta.
Methods
This was a retrospective study based on the registry data-
base in Thalassemia Center, Jakarta. We included patients
who diagnosed as thalassemia major with complete data
on glucose metabolism, thyroid function, pituitary-gonadal
axis, bone profile, bone age, and serum ferritin level. We
analyzed the association between ferritin level, chelation
therapy and type of thalassemia with endocrine profile
using chi-square with the significant value of 0.05.
Results
Complete data on endocrine profile were found in 67
subjects (31 boys, 36 girls), 23 (34%) were diagnosed as
b-thalassemia homozygote and the rest as b-thalassemia/
HbE. The mean age was 16.7±5.8 years. Most of the
patients (63%) received iron chelation therapy with des-
ferrioxamine followed by deferiprone (20%) and only two
patients have not taken any iron chelation therapy yet.
Short stature was found in 65% of subjects, while 20% of
subjects suffered from delayed puberty, 41% had
hypothyroidism, and 29% had retarded bone age. None of
them was diagnosed as DM or IGT, but one diagnosed as
IFG. Hypocalcemia was found in 27% subjects. Subjects
with serum ferritin level ≥ 2,500 ng/mL had increased
risk to develop hypothyroidism, hypocalcemia and hyper-
phosphatemia, even though not statistically significant
(p=0.58, p=0.08, respectively). Serum ferritin level also
not associated with short stature and delayed puberty.
Subjects with thalassemia beta-major had increased risk
to develop hypothyroidism (p=0.036), but no differences
found in the prevalence of short stature, delayed puberty,
hypocalcemia, and hypophosphatemia (p0.17, p=0.91,
p=0.60, respectively). The frequency of transfusion per
year and type of chelation therapy did not influence the
endocrine profiles.
Conclusions
This study showed that the prevalence of short stature
among thalassemia patients is higher in Thalassemia
Center Jakarta, while the risk to develop impaired glu-
cose metabolism is lower, despite of poor compliance in
iron chelation therapy. The risk to develop hypothyroid-
ism, delayed puberty, and hypoparathyroidism were
comparable to other studies.
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